Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

4.270 +0.140 (+3.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Is the Stock Market Open on Memorial Day 2024? ↗
Investors wondering if the stock market is open on Memorial Day in 2024 need look no further as we have the answer to that question! 
Via InvestorPlace
News headline image
7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split ↗
Nvidia is a hot topic among traders on Friday after the company provided investors with details of an NVDA stock split next month. 
Via InvestorPlace
News headline image
NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial ↗
Netlist stock is down on Friday with heavy NLST trading after a court ruled in favor of the company in a patent battle with Micron. 
Via InvestorPlace
Topics Intellectual Property
News headline image
Why Is Verastem (VSTM) Stock Down 62% Today? ↗
Verastem stock is down on Friday with heavy trading of VSTM shares alongside its latest pancreatic cancer clinical trial safety data. 
Via InvestorPlace
News headline image
Dow Surges 50 Points; US Durable Goods Orders Increase In April ↗
 
Via Benzinga
Topics Stocks
News headline image
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? ↗
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant... 
Via Benzinga
News headline image
VSTM Stock Earnings: Verastem Beats EPS for Q1 2024 ↗
VSTM stock results show that Verastem beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Recap: Verastem Q4 Earnings ↗
 
Via Benzinga
News headline image
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news! 
Via InvestorPlace
News headline image
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
News headline image
VSTM Stock Earnings: Verastem Misses EPS for Q4 2023 ↗
VSTM stock results show that Verastem missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
From Verastem Oncology
Via Business Wire
News headline image
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and... 
Via Benzinga
News headline image
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 ↗
Discover AI's top stock selections, meticulously analyzed for 2024, promising more than just returns but a revolution in your portfolio. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
From Verastem Oncology
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.